Understanding the Role of Disability in MS Management

Slides:

Advertisements

Similar presentations

Upfront Combination Therapy vs Step-Up Approach for PAH:

Advertisements

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Multiple sclerosis: Oral Therapies and Beyond

Symptom Control and Enhancing Functioning in Schizophrenia

Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.

Immune Depletion, Immune Modulation, and Immunosuppression in MS: A Review.

Key Issues in Depression: Highlights From APA 2016

Exploring Early Combination Therapy in PAH

Highlights From the 2017 Annual European MS Meeting

Perspectives on Key MS Data From the Annual European MS Meeting

MS Highlights From the 2017 Annual Neurology Meeting

The Clinical Enigma of Cardiogenic Shock

Modifying Disease Course in Alzheimer's Disease

Immune Reconstitution in MS:

What Predicts Disability Progression in Multiple Sclerosis?

Current Controversies in Multiple Sclerosis Management

Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.

Achieving and Maintaining Weight Loss in Obesity: Clinical Evidence for Novel Approaches.

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Optimizing the Treatment of Recurrent/Metastatic SCCHN

A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.

Assessing Disease Progression in MS Treatment

CDK4/6 Inhibitors in Practice

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Novel Therapies for the Treatment of MS

Are We Closer to Personalized Medicine in MS?

Should I Stay or Should I Go?

Expert Insights on Complex Clinical Cases of Edema

Comments on design and sequence of biomarker studies

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

Treating to Target in MS

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Using Heart Rate as a Biomarker in Clinical Practice.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Identifying High-Risk AF Patients

Program Goals Overview Is NEDA a Reasonable Target?

Intro: Biomarkers in RA

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Monoclonal Antibodies in CVD: What Does the Future Hold?

Treatment-Resistant Schizophrenia

Tackling Schizophrenia With Your Patients

Implications of Emerging Treatments for Beta-Thalassemia

Clinical Pearls on Hot Topics in MS

Managing Age-Related Clinical Issues in Hemophilia

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Severe Asthma and Comorbidities

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

Are We Making Progress in the Management of Huntington Disease?

Oral Prostacyclin Pathway Agents in PAH

Reducing Risk for CV Outcomes

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Program Goals Overview Is NEDA a Reasonable Target?

Oral Therapies in MS.

Novel Therapeutics in MS

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Real-World Evidence.

Clinical Comparisons in CTEPH

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

MS, Age, and Immune Function

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

Updates in Progressive MS

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

Anemia Explored.

My PAH Patient.

PCSK9 Inhibitors and Real-World Evidence

Shared Decision Making in MS

Selective Immunomodulation in MS

What's New in NOACs in AF?.

Presentation transcript:

Understanding the Role of Disability in MS Management

Case Study 1

Disease Mechanisms Explaining Disability Worsening in Patient With NEDA

Potential Add-On to MS Treatment

Neurofilaments Biomarkers of Silent Disease Activity

Impact of Comorbidities on Disability Progression

Overlap of Common Perimenopausal and MS Symptoms

Clinical Course of MS

Case Study 2

ORATORIO Subgroup Analysis Upper limb function

ORATORIO Subgroup Analysis Results

ORATORIO-HAND Phase 3b Study Design

MS Length-Dependent Axonopathy Characteristics

Evidence for a Modifiable Disease Activity Component in PMS Trials

Therapeutic Window in Progressive MS

Potential Efficacy of DMT in Progressive MS

Case Study 3

MS Disease Stratification for Treatment

PCORI-Funded Study in MS

Treatment Strategies Escalation vs Induction

MSBase Registry

NEDADI

Strategies for Longitudinal Patient Monitoring FITRiMS

FitRIMS

Strategies for Longitudinal Patient Monitoring FLOODLIGHT

MS Brain Health Initiative

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)